This biotechnology company develops immunotherapeutics utilizing viral vectors to target infectious diseases, autoimmune disorders, and cancer. By harnessing the immune response, the company enables healthcare professionals to enhance patient outcomes in the treatment of these conditions.
Funding
$370K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current vaccines and immunotherapies often struggle to provide lasting protection against recurring persistent diseases. New approaches are needed to effectively modulate the immune system and control these infections, autoimmune disorders, and cancers.
Solution
Virothera is developing gene-based immunotherapeutics using human homologues of virus immune modifiers (virokines) to regulate immune responses in vivo. Their technology uses DNA or RNA for gene therapy to deliver these virokines, offering a potential advantage over cell or antibody-based modalities. Virothera's virokine immune therapeutics (VIT) inhibit chemokine receptors, stimulating the immune system for vaccines. Conversely, their cytokine immune regulators (CIR) bind and signal to regulatory receptors, inhibiting the immune system for treating dysregulated immunity. These technologies are combined with virus-like membranes (VLMs) for antigen delivery, expressing multiple genes of the virus entry complex stabilized in membranes.
Target Audience
The primary target audience includes researchers and clinicians focused on developing novel interventions for infectious diseases, autoimmune disorders, and cancers, particularly those seeking alternatives to traditional vaccine or antibody-based approaches.
Features
- Virokine Immune Therapeutics (VIT) designed to inhibit chemokine receptors and stimulate the immune system.
- Cytokine Immune Regulators (CIR) designed to bind and signal to regulatory receptors, inhibiting the immune system.
- Virus-Like Membranes (VLMs) for antigen delivery, expressing multiple genes of the virus entry complex stabilized in membranes.
- Gene-based delivery of immunomodulatory molecules using DNA or RNA.
- Preclinical proof of concept in an in vivo animal model demonstrating 100% protection against acute HSV-2 disease using VLM DNA.
- Combined VLM and VIT technologies providing complete protection against virus recurrence and reduced reactivated virus secretion in preclinical models.
- Intellectual property portfolio including patents for VLM, VIT, and CIR technologies for DNA, RNA, or protein.